2509 (2509) News
Follow 2509 (2509) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Qyuns Therapeutics Licenses Antibody Program to Caldera
Qyuns Therapeutics said it is licensing an early-stage antibody program to US biotech Caldera Therapeutics in a deal worth up to $750 million plus an upfront fee.
MNA | Nov 05, 2026, 01:56 PM UTC
M
Chainqui Construction reports Sep revenue rise to NT$27.226M
Chainqui Construction Development Co. Ltd. reported Sep revenue of NT$27.226M versus NT$20.648M in 2025, per Taiwan Stock Exchange figures. Jan-Sep revenue was NT$1.354605B versus NT$194.071M.
EARNINGS | Oct 08, 2026, 06:53 AM UTC
M
Chainqui Construction Aug revenue rises to NT$126.2M
Chainqui Construction Development Co. reported Aug revenue of NT$126.2M versus NT$20.7M. Jan–Aug revenue was NT$1,327,379,000 versus NT$173,423,000, per Taiwan Stock Exchange data.
EQUITY | Sep 08, 2026, 06:26 AM UTC